CA1189861A - Derivatives of 2-phenyl-morpholine and their use in therapeutics - Google Patents
Derivatives of 2-phenyl-morpholine and their use in therapeuticsInfo
- Publication number
- CA1189861A CA1189861A CA000416708A CA416708A CA1189861A CA 1189861 A CA1189861 A CA 1189861A CA 000416708 A CA000416708 A CA 000416708A CA 416708 A CA416708 A CA 416708A CA 1189861 A CA1189861 A CA 1189861A
- Authority
- CA
- Canada
- Prior art keywords
- crl
- dose
- morpholine
- tion
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- ZLNGFYDJXZZFJP-UHFFFAOYSA-N 2-phenylmorpholine Chemical class C1NCCOC1C1=CC=CC=C1 ZLNGFYDJXZZFJP-UHFFFAOYSA-N 0.000 title claims description 6
- 239000003814 drug Substances 0.000 title abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 11
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- RLMOVFUYZBCTKX-UHFFFAOYSA-N 4-ethyl-2-phenylmorpholine Chemical compound C1N(CC)CCOC1C1=CC=CC=C1 RLMOVFUYZBCTKX-UHFFFAOYSA-N 0.000 claims abstract description 4
- UBQMBBSAKGENED-UHFFFAOYSA-N 4-methyl-2-(2-methylphenyl)morpholine Chemical compound C1N(C)CCOC1C1=CC=CC=C1C UBQMBBSAKGENED-UHFFFAOYSA-N 0.000 claims abstract description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 abstract description 3
- 230000001430 anti-depressive effect Effects 0.000 abstract description 2
- 239000000935 antidepressant agent Substances 0.000 abstract description 2
- 229940005513 antidepressants Drugs 0.000 abstract description 2
- 230000002631 hypothermal effect Effects 0.000 description 22
- 206010021113 Hypothermia Diseases 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 206010039897 Sedation Diseases 0.000 description 14
- 230000036280 sedation Effects 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000006550 Mydriasis Diseases 0.000 description 9
- 230000004899 motility Effects 0.000 description 9
- RSDOPYMFZBJHRL-UHFFFAOYSA-N Oxotremorine Chemical compound O=C1CCCN1CC#CCN1CCCC1 RSDOPYMFZBJHRL-UHFFFAOYSA-N 0.000 description 8
- 206010021143 Hypoxia Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 206010042008 Stereotypy Diseases 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 230000002093 peripheral effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 206010035039 Piloerection Diseases 0.000 description 5
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 5
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 5
- 229960004046 apomorphine Drugs 0.000 description 5
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 5
- 230000036461 convulsion Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 230000005371 pilomotor reflex Effects 0.000 description 5
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 5
- 229960003147 reserpine Drugs 0.000 description 5
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000822667 Mus musculus Something about silencing protein 10 Proteins 0.000 description 4
- 206010044565 Tremor Diseases 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 230000003518 presynaptic effect Effects 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 235000011121 sodium hydroxide Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960000317 yohimbine Drugs 0.000 description 3
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 3
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 3
- YXWWHNCQZBVZPV-UHFFFAOYSA-N 2'-methylacetophenone Chemical compound CC(=O)C1=CC=CC=C1C YXWWHNCQZBVZPV-UHFFFAOYSA-N 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 239000000842 neuromuscular blocking agent Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- FHQRDEDZJIFJAL-UHFFFAOYSA-N 4-phenylmorpholine Chemical compound C1COCCN1C1=CC=CC=C1 FHQRDEDZJIFJAL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001648 bromium Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-M chlorate Inorganic materials [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- ICLWTJIMXVISSR-UHFFFAOYSA-N gallamine Chemical compound CCN(CC)CCOC1=CC=CC(OCCN(CC)CC)=C1OCCN(CC)CC ICLWTJIMXVISSR-UHFFFAOYSA-N 0.000 description 1
- 229960003054 gallamine Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000035873 hypermotility Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- PCNRQYHSJVEIGH-ASTDGNLGSA-M sodium;5-benzo[e]benzotriazol-2-yl-2-[(e)-2-phenylethenyl]benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC(N2N=C3C4=CC=CC=C4C=CC3=N2)=CC=C1\C=C\C1=CC=CC=C1 PCNRQYHSJVEIGH-ASTDGNLGSA-M 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8122507A FR2517305B1 (fr) | 1981-12-01 | 1981-12-01 | Nouveaux derives de 2-phenyl-morpholine et leur utilisation en therapeutique |
| FR8122507 | 1981-12-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1189861A true CA1189861A (en) | 1985-07-02 |
Family
ID=9264557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000416708A Expired CA1189861A (en) | 1981-12-01 | 1982-11-30 | Derivatives of 2-phenyl-morpholine and their use in therapeutics |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0080940B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPS58103377A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE18043T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU9100482A (cg-RX-API-DMAC7.html) |
| CA (1) | CA1189861A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3269247D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK531582A (cg-RX-API-DMAC7.html) |
| ES (1) | ES517779A0 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2517305B1 (cg-RX-API-DMAC7.html) |
| GR (1) | GR77037B (cg-RX-API-DMAC7.html) |
| IE (1) | IE54330B1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA828758B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648347A (en) * | 1991-04-23 | 1997-07-15 | Glaxo Wellcome Inc. | Arylmorpholine, preparation and use |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2553410B1 (fr) * | 1983-10-14 | 1986-05-16 | Lafon Labor | Nouveaux derives de 2-tolyl-morpholine utiles en therapeutique |
| FR2564462B1 (fr) * | 1984-05-16 | 1986-11-21 | Lafon Labor | Derives de la 2-phenyl-morpholine utiles en therapeutique |
| AU3364493A (en) * | 1992-01-28 | 1993-09-01 | Smithkline Beecham Plc | Compounds as calcium channel antagonists |
| US7294637B2 (en) | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
| EP1318988A2 (en) | 2000-09-11 | 2003-06-18 | Sepracor, Inc. | Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2835669A (en) * | 1958-05-20 | Process for the production of substi- | ||
| GB851311A (en) * | 1958-04-02 | 1960-10-12 | Geigy Ag J R | Morpholine compounds and their production |
| FR1535615A (fr) * | 1967-06-26 | 1968-08-09 | Ct Europ De Rech S Mauvernay | Procédé pour l'obtention de tétrahydro-1, 4-oxazines substituées en 2, 4 et en 2, 2, 4 |
| FR2471378A1 (fr) * | 1979-12-14 | 1981-06-19 | Lafon Labor | Derives de 2-phenyl-morpholine, leur procede de preparation et leur application en therapeutique |
-
1981
- 1981-12-01 FR FR8122507A patent/FR2517305B1/fr not_active Expired
-
1982
- 1982-11-17 GR GR69842A patent/GR77037B/el unknown
- 1982-11-25 DE DE8282402147T patent/DE3269247D1/de not_active Expired
- 1982-11-25 EP EP82402147A patent/EP0080940B1/fr not_active Expired
- 1982-11-25 AT AT82402147T patent/ATE18043T1/de not_active IP Right Cessation
- 1982-11-29 ZA ZA828758A patent/ZA828758B/xx unknown
- 1982-11-29 IE IE2840/82A patent/IE54330B1/en unknown
- 1982-11-29 ES ES517779A patent/ES517779A0/es active Granted
- 1982-11-30 DK DK531582A patent/DK531582A/da not_active Application Discontinuation
- 1982-11-30 AU AU91004/82A patent/AU9100482A/en not_active Abandoned
- 1982-11-30 CA CA000416708A patent/CA1189861A/en not_active Expired
- 1982-12-01 JP JP57211199A patent/JPS58103377A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648347A (en) * | 1991-04-23 | 1997-07-15 | Glaxo Wellcome Inc. | Arylmorpholine, preparation and use |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0254831B2 (cg-RX-API-DMAC7.html) | 1990-11-22 |
| ATE18043T1 (de) | 1986-03-15 |
| AU9100482A (en) | 1983-06-09 |
| EP0080940A3 (en) | 1983-07-06 |
| IE822840L (en) | 1983-06-01 |
| DE3269247D1 (en) | 1986-03-27 |
| FR2517305A1 (fr) | 1983-06-03 |
| IE54330B1 (en) | 1989-08-30 |
| ES8308317A1 (es) | 1983-08-16 |
| JPS58103377A (ja) | 1983-06-20 |
| DK531582A (da) | 1983-06-02 |
| ZA828758B (en) | 1983-09-28 |
| EP0080940B1 (fr) | 1986-02-19 |
| EP0080940A2 (fr) | 1983-06-08 |
| GR77037B (cg-RX-API-DMAC7.html) | 1984-09-04 |
| FR2517305B1 (fr) | 1985-10-25 |
| ES517779A0 (es) | 1983-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1199916A (en) | Benzhydrylsulfinylacetamide derivatives | |
| US3705233A (en) | Phenylaminoethanol derivatives | |
| US2884444A (en) | 2-phenyl-1,3 propane diol dicarbamate | |
| IL31246A (en) | Phenylethananolamine compounds, their preparations and veterinary medicinal products containing them | |
| EP0047536B1 (en) | Substituted propylamines | |
| US3732300A (en) | Phenylaminoethanol derivatives | |
| US3205136A (en) | Antidepressant phenyloxyalkylamines | |
| NO141207B (no) | Analogifremgangsmaate for fremstilling av fysiologisk aktive fenylalkylaminer | |
| US3701808A (en) | Phenylethanolamines | |
| US3832377A (en) | 2-acetamido-2-(3,4-dioxybenzyl)-3-hydroxy-propionitriles | |
| FR2569184A1 (fr) | Derives de 1-(aminophenyl) therapeutique et leur procede de preparation | |
| NO150734B (no) | Fremgangsmaate ved produksjon av olje eller gass gjennom en broenn som strekker seg gjennom en olje- eller gassholdig formasjon | |
| EP0080940B1 (fr) | Nouveaux dérivés de 2-phényl-morpholine et compositions thérapeutiques | |
| CA1152517A (en) | Heterocyclic compounds, processes for their preparation and their use | |
| US3238200A (en) | Oxadiazinediones | |
| US4407822A (en) | Benzamido-alkyl-hydroxamic acid derivatives | |
| US4714699A (en) | 2-tolylmorpholine derivatives and pharmaceutical compositions | |
| US3669837A (en) | Process for producing 3-(3,4-dimethoxyphenyl)l-alanine by resolution | |
| US4126625A (en) | Certain 5-substituted-3-methyl-2-benzofuran acetic acids | |
| US3950335A (en) | 1-(3'-trifluoromethyl-4'-chloro-phenyl)-2-amino-propanes and salts thereof | |
| US3624217A (en) | 2-(substituted)-5,6-dihydro-4h-1,3-thiazines for the control of rice blast | |
| CA1297909C (en) | 1-(aminophenyl)-2-aminoethanone derivatives, the method for their preparation and their use in therapy | |
| US3151148A (en) | Cyano stilbene hypocholesterolemic | |
| US4271194A (en) | Sedative compositions containing (3,4-dichlorophenylsulphinyl)-acetamidoxime and its addition salts and method of use | |
| JPH0774190B2 (ja) | Ｎ，ｎ−ビス（４−フルオロフエニル）カルバモイルアセトヒドロキサム酸およびこれを含有する興奮抗うつ薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |